Ida Manna1, Antonio Gambardella2, Angelo Labate3, Laura Mumoli3, Edoardo Ferlazzo4, Franco Pucci3, Umberto Aguglia5, Aldo Quattrone6. 1. Institute of Molecular Bioimaging and Physiology (IBFM), Section of Germaneto, National Research Council, Catanzaro, Italy. 2. Institute of Neurology, University "Magna Graecia", Germaneto, Catanzaro, Italy. Electronic address: a.gambardella@unicz.it. 3. Institute of Neurology, University "Magna Graecia", Germaneto, Catanzaro, Italy. 4. Regional Epilepsy Centre, Hospital of Reggio Calabria, Reggio Calabria, Italy. 5. Institute of Neurology, University "Magna Graecia", Germaneto, Catanzaro, Italy; Regional Epilepsy Centre, Hospital of Reggio Calabria, Reggio Calabria, Italy. 6. Institute of Molecular Bioimaging and Physiology (IBFM), Section of Germaneto, National Research Council, Catanzaro, Italy; Institute of Neurology, University "Magna Graecia", Germaneto, Catanzaro, Italy.
Abstract
PURPOSE: A synonymous C to T variant at position 3435 (c.3435C>T) is one common polymorphism of the multidrug resistant 1 (MDR1) gene, which encodes the major transmembrane efflux transporter P-glycoprotein. It has been suggested that this polymorphism, and more specifically the 3435CC genotype, may be associated with the response to antiepileptic drug treatment. Here we wished to examine the role of such a candidate variant in a cohort of 175 patients (98 women and 76 men; mean ± SD age: 47.90 ± 17.64) with temporal lobe epilepsy (TLE). METHODS: Patients were classified according to whether they had drug-responsive (n=134) or drug-resistant (n=41) epilepsy. We also enrolled 175 healthy controls (93 women and 82 men; mean ± SD age: 72.5 ± 6.8), matched for sex and ethnicity. RESULTS: Patients and controls were genotyped for detection of the 3435C>T polymorphism, but the analysis showed no significant association between the CC genotype and the risk of drug-resistant epilepsy. CONCLUSION: These findings rule out the MDR1 c.3435C>T polymorphism having a major role or increasing the risk of drug-resistance suggesting a revision is required to determine the contribution of this polymorphism in predicting drug response in epilepsy.
PURPOSE: A synonymous C to T variant at position 3435 (c.3435C>T) is one common polymorphism of the multidrug resistant 1 (MDR1) gene, which encodes the major transmembrane efflux transporter P-glycoprotein. It has been suggested that this polymorphism, and more specifically the 3435CC genotype, may be associated with the response to antiepileptic drug treatment. Here we wished to examine the role of such a candidate variant in a cohort of 175 patients (98 women and 76 men; mean ± SD age: 47.90 ± 17.64) with temporal lobe epilepsy (TLE). METHODS:Patients were classified according to whether they had drug-responsive (n=134) or drug-resistant (n=41) epilepsy. We also enrolled 175 healthy controls (93 women and 82 men; mean ± SD age: 72.5 ± 6.8), matched for sex and ethnicity. RESULTS:Patients and controls were genotyped for detection of the 3435C>T polymorphism, but the analysis showed no significant association between the CC genotype and the risk of drug-resistant epilepsy. CONCLUSION: These findings rule out the MDR1 c.3435C>T polymorphism having a major role or increasing the risk of drug-resistance suggesting a revision is required to determine the contribution of this polymorphism in predicting drug response in epilepsy.